Title
10-week Leucine Supplementation in Cerebral Palsy
The Effects of 10-week Leucine Supplementation on Muscle Growth, Body Composition, Metabolism, Inflammation and Wellbeing of Adolescents and Young Adults With Cerebral Palsy
Phase
N/ALead Sponsor
St Mary's University CollegeStudy Type
InterventionalStatus
Unknown statusIndication/Condition
Cerebral Palsy Ataxic ...Intervention/Treatment
Leucine ...Study Participants
25The purpose of this study is to assess the effects of 10-weeks leucine supplementation on muscle growth, metabolism, body composition, inflammation and wellbeing in adolescents and young adults with CP.
Cerebral palsy (CP) is caused by damage to the developing brain and descending pathways, leading to altered patterns of growth and development. Those with CP may encounter early symptoms of paresis and spasticity, leading to progressive secondary musculoskeletal complications, including increased muscle atrophy and abnormal growth of contractile and non-contractile tissue. This causes significant weakness of the muscle and compromises daily motor function, leading to substantial declines in activities of daily living and independence. As such, interventions aimed at increasing muscle mass or preventing muscle atrophy for those with CP must be established. It is well established that dietary protein ingestion stimulates protein synthesis and inhibits proteolytic pathways, resulting in a positive protein balance and net muscle mass gain. In particular, leucine (a branched chain amino acid; BCAA), has been used to facilitate protein synthesis and muscle growth. Leucine also has anti-inflammatory roles, some of which are central in origin and have been shown to effect mood and features of wellbeing. However, there has been no investigation of the effects of leucine supplementation on any of these parameters in CP. Therefore, the purpose of this study is to assess the effects of 10-weeks leucine supplementation on muscle growth, metabolism, body composition, inflammation and wellbeing in adolescents and young adults with CP.
A taste and calorie-matched placebo
Inclusion Criteria: A diagnosis of spastic cerebral palsy Aged 12-22 years Exclusion Criteria: Orthopaedic surgery of the upper-limbs in the past 12 months Botulinum toxin type A injections in the past 6 months Serial casting in the past 6 months Insufficient cognitive understanding to comply with the assessment procedures and intervention Liver and/or kidney dysfunction
